Back to search results

Inno Cleanse Dietary Supplement for Bloating and Constipation

This study is looking at how a natural dietary supplement called Inno Cleanse™ affects bloating and constipation in healthy men and women. Inno Cleanse™ contains ingredients like cascara sagrada bark powder and senna leaf powder. Some participants will receive Inno Cleanse™, while others will receive a placebo (an inactive capsule). Researchers will measure liver enzymes (Alanine transaminase and Aspartate transferase) at the beginning and after two weeks to see if the supplement has an impact. You might be able to join if you are 18 or older, experience bloating or constipation at least twice a week, and can fast for 12 hours before visits. You cannot join if you are pregnant, breastfeeding, or allergic to any of the supplement's ingredients. The study aims to enroll 30 people, but its current status is unclear.

Study design
This is an interventional study comparing the Inno Cleanse dietary supplement to a placebo. It plans to enroll 30 participants.
What's involved
You would need to fast for at least 12 hours before testing visits. Liver enzymes will be measured at the start of the study and again after two weeks of taking the assigned intervention.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed for two weeks after starting the assigned intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07215351

Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women

Completed
NAAges 18+InterventionalBasic science
University of Memphis
~30 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:Dietary supplement for digestive healthplacebo capsule

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Alanine transaminase
Measured over baseline
+110 more outcomes measured

Conditions

Constipation
Bloating

Explore related trials

BloatingConstipation

Where it's being run

1 sites across 1 states
Tennessee1

Study leadership

  • Richard Bloomer, PhD · PRINCIPAL_INVESTIGATOR · University of Memphis

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

experience regular (2 or more days per week) bloating or constipation
able to fast a minimum of 12 hours prior to testing visit

Exclusion

pregnant, planning to become pregnant, or breastfeeding
sensitivity or allergic to any components of the study product (cascara sagrada bark powder, cape aloe leaves extract, senna leaf powder, frangula bark powder fennel seed powder, bentonite clay, burdock root powder, licorice root extract, slippery elm bark powder, Capiscum annuum L. Fruit powder, milk thistle seed powder, hydroxypropyl methylcellulose, cellulose, and silicon dioxide).
experienced a severe allergic reaction that resulted in emergency care
diagnosed with medical disorders linked to digestive/gut health such as celiac disease, crohn's disease, gastroesophageal reflux disease, heartburn, irritable bowel syndrome, ulcerative colitis, ulcers, etcetera.
experiencing regular diarrhea
active infection or illness
diabetic
hypertensive
cardiovascular disease
breast, uterine, or ovarian cancer
uterine fibroids or endometriosis
taking medications or supplements that may alter gut health including but not limited to diuretics, laxatives, anti-diarrheal, anticholinergic agents, or antispasmodic agents.
previous adverse experience with laxatives
taking medications known to interact with the dietary supplement's ingredients including blood pressure medications, anticoagulants, antiplatelets, blood thinners, cholesterol-lowering medications, diuretics, water pills, estrogen based contraceptives, non-steroidal anti-inflammatory drugs, digoxin, corticosteroids, Monoamine oxidase inhibitors, insulin, medications processed in the liver, diclofenac, fluvastatin, glipizide, ibuprofen, piroxicam, phenytoin, phenobarbital, or secobarbital.
tobacco user
strenuous activity within 24 hours of testing visits
caffeine within 24 hours of testing visit
alcohol within 24 hours of testing visit

What this trial measures

  • Alanine transaminasebaseline

    Alanine transaminase measured as part of metabolic panel in international units per liter

  • Alanine transaminase2 weeks of assigned intervention

    Alanine transaminase measured as part of metabolic panel in international units per liter

  • Aspartate transferasebaseline

    Aspartate transferase measured as part of metabolic panel in international units per liter

  • Aspartate transferase2 weeks of assigned intervention

    Aspartate transferase measured as part of metabolic panel in international units per liter

  • Albuminbaseline

    Albumin measured as part of metabolic panel in grams per deciliter

  • Albumin2 weeks of assigned intervention

    Albumin measured as part of metabolic panel in grams per deciliter

  • Alkaline phosphatasebaseline

    Alkaline phosphatase measured as part of metabolic panel in international units per liter

  • Alkaline phosphatase2 weeks of assigned intervention

    Alkaline phosphatase measured as part of metabolic panel in international units per liter

  • Total bilirubinbaseline

    Total bilirubin measured as part of metabolic panel in milligrams per deciliter

  • Total Bilirubin2 weeks of assigned intervention

    Total bilirubin measured as part of metabolic panel in milligrams per deciliter

  • Blood urea nitrogenbaseline

    Blood urea nitrogen measured as part of metabolic panel in milligrams per deciliter

  • Blood urea nitrogen2 weeks of assigned intervention

    Blood urea nitrogen measured as part of metabolic panel in milligrams per deciliter

  • Calciumbaseline

    Calcium measured as part of metabolic panel in milligrams per deciliter

  • Calcium2 weeks of assigned intervention

    Calcium measured as part of metabolic panel in milligrams per deciliter

  • Carbon dioxidebaseline

    Carbon dioxide measured as part of metabolic panel in millimoles per liter

  • Carbon dioxide2 weeks of assigned intervention

    Carbon dioxide measured as part of metabolic panel in millimoles per liter

  • Chloridebaseline

    Chloride measured as part of metabolic panel in millimoles per liter.

  • Chloride2 weeks of assigned intervention

    Chloride measured as part of metabolic panel in millimoles per liter.

  • Creatininebaseline

    Creatinine measured as part of metabolic panel in milligrams per deciliter

  • Creatinine2 weeks of assigned intervention

    Creatinine measured as part of metabolic panel in milligrams per deciliter

  • Estimated glomerular filtration ratebaseline

    Estimated glomerular filtration rate as part of metabolic panel in milliliters per minute per 1.73

  • Estimated glomerular filtration rate2 weeks of assigned intervention

    Estimated glomerular filtration rate as part of metabolic panel in milliliters per minute per 1.73

  • Blood Glucosebaseline

    Glucose measured as part of metabolic panel in milligrams per deciliter

  • Blood Glucose2 weeks of assigned intervention

    Glucose measured as part of metabolic panel in milligrams per deciliter

  • Potassiumbaseline

    Potassium measured as part of metabolic panel in millimoles per liter.

  • Potassium2 weeks of assigned intervention

    Potassium measured as part of metabolic panel in millimoles per liter.

  • Sodiumbaseline

    Sodium measured as part of metabolic panel in millimoles per liter.

  • Sodium2 weeks of assigned intervention

    Sodium measured as part of metabolic panel in millimoles per liter.

  • Total Globulinbaseline

    Total Globulin measured as part of metabolic panel in grams per deciliter

  • Total Globulin2 weeks of assigned intervention

    Total Globulin measured as part of metabolic panel in grams per deciliter

  • Total Proteinbaseline

    Total Protein measured as part of metabolic panel in grams per deciliter

  • Total Protein2 weeks of assigned intervention

    Total Protein measured as part of metabolic panel in grams per deciliter

  • Albumin/globulin ratiobaseline

    Albumin/globulin ratio measured as part of metabolic panel

  • Albumin/globulin ratio2 weeks of assigned intervention

    Albumin/globulin ratio measured as part of metabolic panel

  • Blood urea nitrogen/creatinine ratiobaseline

    Blood urea nitrogen/creatinine ratio measured as part of metabolic panel

  • Blood urea nitrogen/creatinine ratio2 weeks of assigned intervention

    Blood urea nitrogen/creatinine ratio measured as part of metabolic panel

  • Hematocritbaseline

    Hematocrit as part of a complete blood count panel measured as percentage

  • Hematocrit2 weeks of assigned intervention

    Hematocrit as part of a complete blood count panel measured as percentage

  • Hemoglobinbaseline

    Hemoglobin as part of a complete blood count panel measured in grams per deciliter

  • Hemoglobin2 weeks of assigned intervention

    Hemoglobin as part of a complete blood count panel measured in grams per deciliter

  • Mean corpuscular volumebaseline

    Mean corpuscular volume as part of a complete blood count panel measured in femtoliters

  • Mean corpuscular volume2 weeks of assigned intervention

    Mean corpuscular volume as part of a complete blood count panel measured in femtoliters

  • Mean corpuscular hemoglobinbaseline

    Mean corpuscular hemoglobin as part of a complete blood count panel measured in picograms

  • Mean corpuscular hemoglobin2 weeks of assigned intervention

    Mean corpuscular hemoglobin as part of a complete blood count panel measured in picograms

  • Mean corpuscular hemoglobin concentrationbaseline

    Mean corpuscular hemoglobin concentration as part of a complete blood count panel measured in grams per deciliter

  • Mean corpuscular hemoglobin concentration2 weeks of assigned intervention

    Mean corpuscular hemoglobin concentration as part of a complete blood count panel measured in grams per deciliter

  • Red cell distribution widthbaseline

    Red cell distribution width as part of a complete blood count panel measured as a percentage

  • Red cell distribution width2 weeks of assigned intervention

    Red cell distribution width as part of a complete blood count panel measured as a percentage

  • Plateletsbaseline

    Platelets as part of a complete blood count panel measured as a count per 1000 per microliter

  • Platelets2 weeks of assigned intervention

    Platelets as part of a complete blood count panel measured as a count per 1000 per microliter

  • Specific gravitybaseline

    Specific gravity as measured as part of urinalysis (no units)

  • Specific gravity2 weeks of assigned intervention

    Specific gravity as measured as part of urinalysis (no units)

  • pHbaseline

    pH as measured as part of urinalysis (no units)

  • pH2 weeks of assigned intervention

    pH as measured as part of urinalysis (no units)

  • Urine colorbaseline

    Urine color as reported as part of urinalysis (no units)

  • Urine color2 weeks of assigned intervention

    Urine color as reported as part of urinalysis (no units)

  • Urine Appearancebaseline

    Urine Appearance as reported as part of urinalysis (no units)

  • Urine Appearance2 weeks of assigned intervention

    Urine Appearance as reported as part of urinalysis (no units)

  • White Blood Cell esterasebaseline

    White blood cell esterase as measured as part of urinalysis, if present

  • White blood cell esterase2 weeks of assigned intervention

    White blood cell esterase as measured as part of urinalysis, if present

  • Proteinbaseline

    Protein as measured as part of urinalysis, if present

  • Protein2 weeks of assigned intervention

    Protein as measured as part of urinalysis, if present

  • Glucosebaseline

    Glucose as measured as part of urinalysis, if present

  • Glucose2 weeks of assigned intervention

    Glucose as measured as part of urinalysis, if present

  • Ketonesbaseline

    Ketones as measured as part of urinalysis, if present

  • Ketones2 weeks of assigned intervention

    Ketones as measured as part of urinalysis, if present

  • Occult bloodbaseline

    Occult blood as measured as part of urinalysis, if present

  • Occult blood2 weeks of assigned intervention

    Occult blood as measured as part of urinalysis, if present

  • Bilirubinbaseline

    Bilirubin as measured as part of urinalysis, if present

  • Bilirubin2 weeks of assigned intervention

    Bilirubin as measured as part of urinalysis, if present

  • Urobilinogenbaseline

    Urobilinogen as measured as part of urinalysis in milligrams per deciliter

  • Urobilinogen2 weeks of assigned intervention

    Urobilinogen as measured as part of urinalysis in milligrams per deciliter

  • Microscopic examinationbaseline

    Microscopic examination as reported as part of urinalysis, if indicated

  • Microscopic examination2 weeks of assigned intervention

    Microscopic examination as reported as part of urinalysis, if indicated

  • Total Cholesterolbaseline

    Total Cholesterol as reported as part of lipid panel in milligrams per deciliter

  • Total Cholesterol2 weeks of assigned intervention

    Total Cholesterol as reported as part of lipid panel in milligrams per deciliter

  • Triglyceridesbaseline

    Triglycerides as reported as part of lipid panel in milligrams per deciliter

  • Triglycerides2 weeks of assigned intervention

    Triglycerides as reported as part of lipid panel in milligrams per deciliter

  • High-Density Lipoprotein Cholesterolbaseline

    High-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter

  • High-Density Lipoprotein Cholesterol2 weeks of assigned intervention

    High-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter

  • Very Low-Density Lipoprotein Cholesterolbaseline

    Very Low-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter

  • Very Low-Density Lipoprotein Cholesterol2 weeks of assigned intervention

    Very Low-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter

  • Low-Density Lipoprotein Cholesterolbaseline

    Low-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter

  • Low-Density Lipoprotein Cholesterol2 weeks of assigned intervention

    Low-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter

  • Mood questionnairebaseline

    Visual analog scale used to assess mood (attentive, tired, alert, groggy, focused, sluggish, energetic, lethargic, fatigued, mental clarity, motivation, happiness, and feeling from 0 (None) to 10 (Extreme) as well as "Flushed out" from 0 (not at all) to 10 (completely empty)

  • Mood questionnaire2 weeks of assigned intervention

    Visual analog scale used to assess mood (attentive, tired, alert, groggy, focused, sluggish, energetic, lethargic, fatigued, mental clarity, motivation, happiness, and feeling from 0 (None) to 10 (Extreme) as well as "Flushed out" from 0 (not at all) to 10 (completely empty)

  • 36-item short form surveybaseline

    36-item questionnaire that measures health-related quality of life with responses used to calculate scores on a scale of 0-100, where higher scores indicate better health.

  • 36-item short form survey2 weeks of assigned intervention

    36-item questionnaire that measures health-related quality of life with responses used to calculate scores on a scale of 0-100, where higher scores indicate better health.

  • Tolerability Questionnairebaseline

    18 item questionnaire covering upper abdominal, lower abdominal, and other symptoms using a 0-9 scale (0-no problem at all to 9-the worst it has ever been)

  • Tolerability Questionnaire1 day of assigned treatment

    18 item questionnaire covering upper abdominal, lower abdominal, and other symptoms using a 0-9 scale (0-no problem at all to 9-the worst it has ever been)

  • Tolerability Questionnaire3 days of assigned treatment

    18 item questionnaire covering upper abdominal, lower abdominal, and other symptoms using a 0-9 scale (0-no problem at all to 9-the worst it has ever been)

  • Tolerability Questionnaire1 week of assigned treatment

    18 item questionnaire covering upper abdominal, lower abdominal, and other symptoms using a 0-9 scale (0-no problem at all to 9-the worst it has ever been)

  • Tolerability Questionnaire2 weeks of assigned treatment

    18 item questionnaire covering upper abdominal, lower abdominal, and other symptoms using a 0-9 scale (0-no problem at all to 9-the worst it has ever been)

  • Bristol Chart3 days before baseline

    Self-reported number and consistency of daily bowel movements

  • Bristol Chart2 days before baseline

    Self-reported number and consistency of daily bowel movements

  • Bristol Chart1 day before baseline

    Self-reported number and consistency of daily bowel movements

  • Bristol Chart1 day of assigned treatment

    Self-reported number and consistency of daily bowel movements

  • Bristol Chart2 days on assigned treatment

    Self-reported number and consistency of daily bowel movements

  • Bristol Chart3 days of assigned treatment

    Self-reported number and consistency of daily bowel movements

  • Bristol Chart7 days of assigned treatment

    Self-reported number and consistency of daily bowel movements

  • Bristol Chart14 days of assigned treatment

    Self-reported number and consistency of daily bowel movements

  • Weightbaseline

    Body weight measured in kg

  • Weight2 weeks of assigned treatment

    Body weight measured in kg

  • Skin agebaseline

    a quantitative skin age based on skin parameters will be determined by the 3D P Plus system

  • Skin age2 weeks of assigned treatment

    a quantitative skin age based on skin parameters will be determined by the 3D P Plus system

  • Diastolic blood pressurebaseline

    Diastolic blood pressure will be measured using an automated blood pressure machine in units millimeters of mercury

  • Diastolic blood pressure2 weeks of assigned treatment

    Diastolic blood pressure will be measured using an automated blood pressure machine in units millimeters of mercury

  • Systolic blood pressurebaseline

    Systolic blood pressure will be measured using an automated blood pressure machine in units millimeters of mercury

  • Systolic blood pressure2 weeks of assigned treatment

    Systolic blood pressure will be measured using an automated blood pressure machine in units millimeters of mercury

  • Heart ratebaseline

    Heart rate will be measured using an automated blood pressure machine in units beats per minute

  • Heart Rate2 weeks of assigned treatment

    Hear rate will be measured using an automated blood pressure machine in units beats per minute